Emergent BioSolutions Inc (NYSE:EBS)
| 2.15 Delayed Data As of Nov 29 |  +0.14 / +6.97%Today’s Change | 1.81 Today|||52-Week Range 16.66 | -81.80% Year-to-Date |
Latest EBS News | Press Releases
| Emergent (EBS) Gets $75M BARDA Contract for Anthrax Vaccine Nov 29 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 2.01 |
| Today’s open | 2.00 |
| Day’s range | 2.00 - 2.36 |
| Volume | 1,654,791 |
| Average volume (3 months) | 2,102,808 |
| Market cap | $107.8M |
Data as of 3:59pm ET, 11/29/2023
Growth & Valuation
| Earnings growth (last year) | -203.50% |
| Earnings growth (this year) | +29.90% |
| Earnings growth (next 5 years) | +34.00% |
| Revenue growth (last year) | -37.47% |
| P/E ratio | NM |
| Price/Sales | 0.53 |
| Price/Book | 0.08 |
Competitors
| ---- | ||
| --Lexagene Holdings In... | 0.00 | 0.00% |
| LPTXLeap Therapeutics In... | +0.03 | +1.22% |
| ---- |
Data as of 3:59pm ET, 11/29/2023
Financials
| Next reporting date | February 22, 2024 |
| EPS forecast (this quarter) | $1.67 |
| Annual revenue (last year) | $1.1B |
| Annual profit (last year) | -$223.8M |
| Net profit margin | -19.97% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Gaithersburg, Maryland |
Forecasts
